Drug intelligence / Profile preview

Abacavir hydroxyacetate

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

Abacavir hydroxyacetate is an orally active inhibitor of Interleukin-20 (IL-20) and Psoriasis-Related IL-20-Stimulated Gene (PRINS). It functions as an immune modulator, reducing the proliferation rate of skin cells, and is being investigated for the research of inflammatory skin problems, such as psoriasis. Studies in mice have shown that Abacavir hydroxyacetate effectively controls psoriasis, demonstrating a superior effect compared to methotrexate in reducing PRINS and IL-20 concentrations and the area of skin lesions. This compound is currently for research use only.

Brand names: Prurisol
Other names: Abacavir hydroxyacetateAbacavir acetate

Targets

Human immunodeficiency virus type 1 reverse transcriptaseHLA-B*57:01 (Human leukocyte antigen B*57:01)

Beyond the preview

Go deeper on Abacavir hydroxyacetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abacavir hydroxyacetate.

Explore the full profile